Facebook tracking pixel
L71.9
ICD-10-CM
Acne Rosacea

Learn about acne rosacea, also known as papulopustular rosacea or acneiform rosacea, including diagnosis codes, clinical documentation tips, and healthcare best practices. This resource provides information for accurate medical coding and improved patient care related to rosacea subtypes and treatment. Find details on managing and documenting this chronic inflammatory skin condition for optimal clinical outcomes.

Also known as

Papulopustular Rosacea
Acneiform Rosacea

Diagnosis Snapshot

Key Facts
  • Definition : Chronic inflammatory skin condition causing redness, bumps, and visible blood vessels, primarily on the face.
  • Clinical Signs : Facial flushing, persistent redness, papules, pustules, telangiectasia, burning or stinging sensation.
  • Common Settings : Primary care, dermatology, telehealth consultations for mild cases, specialist referrals for severe or ocular rosacea.

Related ICD-10 Code Ranges

Complete code families applicable to AAPC L71.9 Coding
L71.-

Rosacea

Inflammatory skin condition causing redness, pimples, and visible blood vessels.

L70.-

Acne

Skin condition characterized by blackheads, whiteheads, and pimples.

L57.-

Dermatitis

General term for inflammation of the skin causing itching, redness, and rash.

Code-Specific Guidance

Decision Tree for

Follow this step-by-step guide to choose the correct ICD-10 code.

Is the diagnosis Acne Rosacea or a variant?

Code Comparison

Related Codes Comparison

When to use each related code

Description
Facial redness, visible blood vessels, and small pimples.
Facial redness, flushing, and burning sensation.
Enlarged nose with thickened skin, often bumpy.

Documentation Best Practices

Documentation Checklist
  • Rosacea subtype: Papulopustular/Acneiform
  • Document presence of papules and pustules
  • Exclude acne vulgaris with DDx
  • Note distribution (face, cheeks, nose)
  • Record triggers (sun, heat, alcohol)

Coding and Audit Risks

Common Risks
  • Rosacea Subtype Coding

    Incorrect coding of specific rosacea subtypes (e.g., papulopustular, erythematotelangiectatic) can lead to inaccurate billing and reporting.

  • Acne vs. Rosacea Confusion

    Miscoding acne (L70.0) for rosacea (L71.x) due to similar presentations can impact quality metrics and reimbursement.

  • Severity Documentation Lack

    Insufficient documentation of rosacea severity (mild, moderate, severe) may affect medical necessity reviews and treatment planning.

Mitigation Tips

Best Practices
  • ICD-10-CM L71.8, Rosacea CDI: Trigger avoidance documentation.
  • Sun protection, gentle cleansers vital. CPT 7000-7999 for Dx tests.
  • Topical treatments, oral antibiotics per guidelines. HCC coding impacts.
  • Demodex mites, diet impact noted. Optimize coding for reimbursement.
  • Manage flares, reduce triggers. L71.8 compliant documentation key.

Clinical Decision Support

Checklist
  • 1. Centrofacial erythema, telangiectasia? (ICD-10: L71.9)
  • 2. Papules, pustules present? Exclude acne vulgaris (ICD-10: L70.0)
  • 3. Ocular symptoms? Consider ophthalmology referral (ICD-10: H01.1)
  • 4. Phymatous changes? Document subtype (ICD-10: L71.1)
  • 5. Trigger history documented? Patient education provided (e.g., sun, alcohol)

Reimbursement and Quality Metrics

Impact Summary
  • ICD-10-CM L71.8 accurate coding maximizes Acne Rosacea reimbursement.
  • Rosacea subtype coding impacts quality reporting metrics and severity scores.
  • Precise Acne Rosacea diagnosis improves hospital revenue cycle management.
  • Correct Papulopustular Rosacea coding minimizes claim denials and audits.

Streamline Your Medical Coding

Let S10.AI help you select the most accurate ICD-10 codes. Our AI-powered assistant ensures compliance and reduces coding errors.

Frequently Asked Questions

Common Questions and Answers

Q: How can I differentiate acne rosacea (papulopustular rosacea) from acne vulgaris in adult patients presenting with persistent centrofacial erythema and inflammatory papules?

A: Differentiating acne rosacea, particularly the papulopustular subtype also known as acneiform rosacea, from acne vulgaris can be challenging due to overlapping clinical presentations. However, several key features can aid in accurate diagnosis. In acne rosacea, comedones (blackheads and whiteheads) are absent, a crucial distinguishing factor from acne vulgaris. Persistent centrofacial erythema, including flushing and telangiectasia, is a hallmark of rosacea and is less common in acne. While both conditions present with inflammatory papules and pustules, their distribution differs. In rosacea, these lesions tend to be concentrated in the central face (cheeks, nose, chin, and forehead), whereas acne commonly affects a broader area, including the back and chest. Consider patient age, as adult-onset acne raises suspicion for rosacea. A detailed patient history focusing on triggers such as sun exposure, spicy food, alcohol, and emotional stress can also help differentiate, as these factors are more strongly associated with rosacea flares. Explore how a comprehensive assessment combining clinical presentation, patient history, and trigger identification can improve diagnostic accuracy in differentiating these two conditions. Consider implementing standardized questionnaires for assessing rosacea severity and trigger frequency to aid in diagnosis and treatment planning.

Q: What are the evidence-based first-line topical treatment options for mild to moderate acne rosacea with papules and pustules, and how do I address patient concerns regarding potential adverse effects like burning and stinging?

A: Topical treatments are the cornerstone of managing mild to moderate acne rosacea, especially the papulopustular subtype characterized by papules and pustules. Metronidazole, azelaic acid, and ivermectin are considered first-line options, with demonstrated efficacy in reducing inflammation and lesion counts. When initiating therapy, address patient concerns regarding potential adverse effects like burning and stinging, which are common, especially with metronidazole. Explain that these sensations are usually transient and tend to diminish with continued use. Recommend starting with a low concentration and applying a thin layer once daily, gradually increasing the frequency to twice daily as tolerated. Advise patients to use gentle, fragrance-free cleansers and moisturizers to minimize irritation. Consider implementing a short-term course of topical corticosteroids, such as hydrocortisone, for localized areas of severe inflammation, but avoid long-term use due to the risk of skin atrophy and steroid-induced rosacea. Explore how combination therapy utilizing different topical agents with complementary mechanisms of action may enhance efficacy while minimizing side effects. Learn more about patient education strategies to improve adherence and treatment outcomes.

Quick Tips

Practical Coding Tips
  • Code L71.8 for unspecified Rosacea
  • Query provider for subtype clarity
  • Document pustules/papules if present
  • Consider L71.0 for rhinophyma
  • Check ICD-10-CM guidelines for Rosacea

Documentation Templates

Patient presents with symptoms consistent with acne rosacea, also known as papulopustular rosacea or acneiform rosacea.  Clinical findings include erythema, telangiectasia, and papules and pustules primarily affecting the central face.  The patient denies any burning or stinging sensations.  No ocular involvement is noted.  Differential diagnoses considered include acne vulgaris, perioral dermatitis, and seborrheic dermatitis.  The diagnosis of rosacea is based on clinical presentation and patient history.  Treatment plan includes topical metronidazole gel 1% twice daily and avoidance of known triggers such as sun exposure, spicy foods, and alcohol.  Patient education provided on rosacea management, including the chronic nature of the condition and the importance of adherence to the prescribed treatment regimen.  Follow-up scheduled in four weeks to assess treatment response and adjust therapy as needed.  ICD-10 code L71.9 Rosacea, unspecified, assigned.  Medical billing codes for evaluation and management services, as well as dispensed medications, will be generated accordingly.